Evidence map›Paper›PMID 40699760›Full record

ArticleCurrent issues in molecular biology2025

Impact of SARS-CoV-2 Variant NSP6 on Pathogenicity: Genetic Analysis and Cell Biology.

Yangye Gao, Peng Ni, Yanqiao Hua, Shuaiyin Chen, Rongguang Zhang

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yangye GaoDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Peng NiDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Yanqiao HuaDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Shuaiyin ChenDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0001-6129-0310
Rongguang ZhangDepartment of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0001-9961-2434

Funding

National Natural Science Foundation of China 82160634
6 · The paper itself

Abstract

SARS-CoV-2 nonstructural protein (NSP) 6 is one of the factors affecting viral pathogenicity. Mutations in NSP6 continuously emerge during viral transmission and are closely associated with alterations in viral pathogenicity. This study investigated the structural and functional impacts of NSP6 mutations by analyzing NSP6 proteins from the Wuhan-Hu-1/B (WT) strain and predominant variants Alpha, XBB.1.16, BA.2.86, and JN.1 using bioinformatics, transcriptomics, and cellular experiments. The results demonstrate that the V3593F mutation decreased the β-sheet proportion and modified hydrogen bonding patterns, while the L3829F mutation enhanced structural stability by promoting random coils. The R3821K substitution exposed lysine residues, potentially enhancing molecular interactions. Combined transcriptomic profiling and functional assays revealed that WT-NSP6 significantly inhibited poly (I: C)-induced immune factor transcription and reduced the phosphorylation levels of p-IRF3 and p-STAT1, effects absent in the XBB.1.16 variant. Furthermore, WT-NSP6 markedly activated p-AKT and p-mTOR expression, with JN.1-NSP6 maintaining limited capacity to upregulate p-mTOR. However, p53 inhibitor treatment reversed Alpha-NSP6- and BA.2.86-NSP6-upregulated p-mTOR protein expression in cells. This study demonstrates that a high frequency of NSP6 mutations alters NSP6's structure, impairing the type I interferon signaling pathway and affecting host antiviral responses through the p53-AKT-mTOR signaling pathway. These findings contribute to the understanding of evolution, immune evasion, and viral pathogenesis mechanisms, with potential implications for the development of antiviral therapies and preventive strategies for this viral infection.

Indexed as

bioinformaticscell signaling pathwaygene mutationnonstructural protein 6SARS-CoV-2transcriptomics

Identifiers

PMID40699760
PMCPMC12109688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.